Floatz logo

Ppsv23

Bladder Carcinoma

National Cancer Institute (NCI)vaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

31 Active assets in the Bladder Carcinoma cohort.

Asset / SponsorPhaseRating
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC
Defactinib
National Cancer Institute (NCI)
Phase 2CCC
Binimetinib
National Cancer Institute (NCI)
Phase 2CCC
Osimertinib
National Cancer Institute (NCI)
Phase 2CCC

View all 34 →

Same molecule, other indications

Ppsv23 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
pneumococcal infectionDormant
BB
Indicative ·
69 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →